Clinical trials
Metastatic Lung Cancer clinical trials
Below are recruiting metastatic lung cancer clinical trials, each written for real people, not researchers. We’re tracking 1,193 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07647094RecruitingEarly Phase 1
Chemotherapy plus immunotherapy for advanced squamous lung cancer
This trial tests a combination of three drugs—two chemotherapy medications (carboplatin and nab-paclitaxel) plus an immunotherapy drug (serplulimab)—as a first-line treatment for advanced squamous cell non-small cell lung cancer. The goal is to see if this combination works better than standard treatment and is safe for patients who haven't received prior systemic cancer treatment.
Quzhou, ZhejiangAges 18–75 - NCT07660094RecruitingPhase 3
New treatment for advanced lung cancer that has stopped responding to immunotherapy
This trial tests a new investigational medicine (aglatimagene besadenovec) plus pembrolizumab against standard chemotherapy (docetaxel) for people with stage IV non-squamous lung cancer that has stopped responding to pembrolizumab. The new treatment is given as a tumor injection (like a biopsy) along with a pill (prodrug) and an infusion of pembrolizumab. The goal is to see if it can re-engage the immune system to fight the cancer.
New York, New YorkAges 18 years+ - NCT07662395RecruitingPhase 2/Phase 3
New drug plus chemo for advanced squamous lung cancer
This trial tests a new drug (SCTB41) combined with chemotherapy for people with advanced squamous non-small cell lung cancer who have not had any prior treatment. It aims to see if this combination works better than standard therapy.
Guangzhou, GuangdongAges 18 years+ - NCT06816966Enrolling by invitationPhase 2
Chemo-immunotherapy with split radiation for extensive-stage lung cancer
This trial tests a combination of chemotherapy, immunotherapy, and a special type of radiation given in split sessions for people with extensive-stage small cell lung cancer. The goal is to see if this approach can help control the cancer better.
Fuzhou, FujianAges 18 years+ - NCT06281964Enrolling by invitationPhase 3
New pill for EGFR Exon 20 lung cancer
This study tests a new pill called PLB1004 for people whose lung cancer has a specific EGFR mutation (exon 20 insertion). It is for those who have not yet had any treatment for their advanced cancer.
Guangzhou, GuangzhouAges 18 years+ - NCT05053555Recruiting
High-dose radiation treatment for hard-to-remove liver tumors
This study uses a form of targeted radiation placed inside/near the liver to treat liver tumors that can’t be surgically removed. It’s meant to shrink or control tumors, especially when they sit near blood vessels or other sensitive organs.
Houston, TexasAges 19 years+ - NCT06024837Recruiting
Testing spectral CT for colorectal cancer spread to liver or belly
This study tests a new type of CT scan (spectral CT) to see how well it detects colorectal cancer that has spread to the liver or belly lining. It may help doctors better plan surgery to remove all the cancer.
Saint-EtienneAges Any age - NCT06052345Recruiting
Nerve damage from paclitaxel in breast cancer patients
This study looks at how paclitaxel chemotherapy may affect the nerves in the hands and feet (peripheral neuropathy) in women with early breast cancer. It aims to find early signs of nerve damage, understand risk factors, and track how it impacts your daily life and lifestyle.
Solna, Stockholm CountyAges 18 years+ - NCT05955170RecruitingPhase 2
Tucatinib plus oral chemo and trastuzumab for metastatic HER2+ breast cancer
This Phase 2 trial studies tucatinib combined with oral etoposide and trastuzumab in people with metastatic HER2-positive breast cancer, aiming to slow cancer growth. You may be eligible if you previously had progression on a similar HER2-targeted treatment or cannot take capecitabine for medical reasons.
Clermont-Ferrand, Clermont FerrandAges 18 years+ - NCT06959537RecruitingPhase 1
Combination drug therapy for triple negative breast cancer
This trial tests a new combination of three drugs (cyclophosphamide, axatilimab, and retifanlimab) for people with metastatic triple negative breast cancer. The goal is to see if adding a low dose of chemotherapy can make the immunotherapy work better.
Houston, TexasAges 18 years+ - NCT06832202RecruitingPhase 2
HLX22 plus Enhertu for HR+, HER2-low breast cancer
This trial tests a new drug, HLX22, combined with Enhertu (trastuzumab deruxtecan) for people with advanced breast cancer that is hormone receptor positive and HER2-low. The goal is to see if the combination works better than Enhertu alone.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05954429RecruitingPhase 2
Study of fruquintinib plus immunotherapy after standard CRC treatment
This trial studies fruquintinib combined with serplulimab (an immune therapy) for advanced colorectal cancer that has spread and is no longer responding to standard treatments. It may help by slowing the cancer’s growth and improving outcomes after the usual options have been tried.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT04090567RecruitingPhase 2
Olaparib with two partners for advanced BRCA breast cancer
This trial tests whether the drug olaparib works better when combined with cediranib or AZD6738 in people with advanced or metastatic BRCA (inherited) breast cancer. It may help shrink tumors or slow cancer growth after prior treatment with a PARP inhibitor.
Houston, TexasAges 18 years+ - NCT07062263RecruitingPhase 3
Trastuzumab with chemo for HER2+ bile duct cancer
This trial tests if adding trastuzumab to standard chemotherapy can help people with advanced bile duct or gallbladder cancer that tests positive for HER2. The study aims to see if the combination works better than chemotherapy alone.
Muzaffarpur, BiharAges 18–99 - NCT07065435RecruitingPhase 2
RC48 with Avastin or Pyrotinib for HER2+ breast cancer after T-DXd
This trial tests a new combination of drugs (RC48 plus either Avastin or Pyrotinib) for people with HER2-positive breast cancer that has spread and has stopped responding to the drug T-DXd. The goal is to see if these combinations can help shrink tumors and control the cancer longer.
Nanjing, JiangsuAges 18–75 - NCT06689163RecruitingPhase 1/Phase 2
Study of HRS-1167 with abiraterone for metastatic prostate cancer
This trial tests a new combination of two study drugs (HRS-1167 and abiraterone with prednisone) for men with prostate cancer that has spread beyond the prostate. The goal is to see if the combination works better than current treatments.
Hefei, AnhuiAges 18 years+ - NCT07446452RecruitingPhase 2
Combination treatment for HER2-low advanced breast cancer
This trial tests a combination of two drugs, disitamab vedotin and bevacizumab, for people with a specific type of advanced breast cancer called HER2-low. It is designed for those who have already been treated with a drug called T-DXd and need further options.
Nanjing, JiangsuAges 18–75 - NCT06439888RecruitingPhase 1/Phase 2
Immune cells plus radiation for limited-stage cancer spread
This trial tests whether giving immune-supporting cells (lymphocytes) alongside focused radiation (SBRT) can help control limited cancer spread. People with 1 to 5 small tumors that can all be radiated within two weeks may be eligible.
LyonAges 18 years+ - NCT06962267RecruitingPhase 2
Study of TQB2916 with chemo for advanced pancreatic cancer
This trial tests a new drug (TQB2916) combined with standard chemotherapy (gemcitabine and nab-paclitaxel) as a first treatment for metastatic pancreatic cancer. It aims to see if the combination works better than chemo alone.
Beijing, Beijing MunicipalityAges 18–75 - NCT07454642RecruitingPhase 1
AVA6103 for advanced FAP-positive solid tumors
This trial tests a new drug called AVA6103 for certain advanced cancers that show a protein called FAP. It is for people who have already tried other treatments or cannot take them, and aims to see if the drug is safe and helps shrink tumors.
Grand Rapids, MichiganAges 18 years+ - NCT05896839RecruitingPhase 1/Phase 2
Immunotherapy with prednisone and sirolimus for transplant skin cancer
This early-phase study tests whether adding immunotherapy (nivolumab and ipilimumab) to prednisone and sirolimus can control advanced skin cancers in people with kidney transplants. It aims to see how well the treatment works and how safe it is for transplant recipients.
La Jolla, CaliforniaAges 18 years+ - NCT07535112RecruitingPhase 1
Testing BAY 3771249 for Advanced Colorectal Cancer With KRAS Mutation
This early-stage study tests a new drug called BAY 3771249 in people with advanced colorectal cancer that has a specific genetic change (KRAS G12D mutation). Researchers want to learn if it's safe and whether it helps shrink tumors.
Phoenix, ArizonaAges 18 years+ - NCT05257993RecruitingPhase 1/Phase 2
Pancreatic cancer trial testing JPI-547 with standard chemo
This study tests whether adding JPI-547 to standard chemotherapy (modified FOLFIRINOX or gemcitabine with nab-paclitaxel) is safe and tolerable in people with advanced pancreatic cancer. If it works, it may improve treatment options for cancers that have spread or cannot be removed with surgery.
Gyeonggi-doAges 19–79 - NCT07222800RecruitingPhase 3
Testing a new drug plus chemo for stage 4 colorectal cancer
This study tests a new experimental drug (PF-08634404) combined with standard chemotherapy for people with stage 4 colorectal cancer who have not yet been treated for their advanced disease. The goal is to see if the combination helps shrink or slow the growth of tumors.
Chandler, ArizonaAges 18 years+
Hear when a new Metastatic Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic lung cancer?
- Yes. Clin2 currently lists 1,193 recruiting metastatic lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Non Small Cell Lung Cancer Metastatic
- Non Small Cell Lung Cancer
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Advanced or Metastatic Non-small Cell Lung Cancer
- Lung Cancer (Locally Advanced or Metastatic)
- Lung Cancer Non-Small Cell Cancer (NSCLC)
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Metastatic Breast Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.